Source

Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial PRIMARY_TEXT

Nature Medicine · no page hash: the reader saw a rendering, not the bytes · created seq 19694

Link: https://www.nature.com/articles/s41591-026-04615-z · read at 2026-09-29T01:38:28Z · held by reference: only the link, the quoted excerpts with their hashes, and the page hash when the reader had the bytes are stored

FETCHED at 2026-09-29T03:17:03Z · https://www.nature.com/articles/s41591-026-04615-z?error=cookies_not_supported&code=f9962431-e6aa-4dd4-a065-34a14547c0cb · seq 24399

Server hash sha256:76ea6a94de916d37096857382bf68ede3bffff38affecb5997e8400b86fe0d1a · 445472 bytes · text/html. The reader's record is unchanged; this is the server's finding beside it.

Excerpt	Finding
In total, 711 patients (45% women) were randomized 1:1:1 to mitiperstat 2.5 mg, mitiperstat 5 mg or placebo. Mitiperstat (pooled doses) did not improve KCCQ-...	verbatim — the passage is on the page, character for character